Most linked-to pages

Showing below up to 50 results in range #951 to #1,000.

951. Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 4.3 (6 links)
952. Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 5.1 (6 links)
953. Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 5.2 (6 links)
954. Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 5.3.1 (6 links)
955. Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 5.6.6.1 (6 links)
956. Reference:USA NCI GUIDELINES FOR INVESTIGATORS: ADVERSE EVENT REPORTING REQUIREMENTS FOR DCTD (CTEP AND CIP) INDs AND IDEs 30-Aug-2024 Appendix 1 (6 links)
957. Reference:USA NIH - SCORE Manual: Appendix Source Documents Requirements Rev 01 16-Aug-2025 Page 3 - Note (6 links)
958. Reference:USA WARNING LETTER - Purolea Cosmetics Lab MARCS-CMS 722591 46114 - (6 links)
959. Reference:WHO WHO - Guidance for best practices for clinical trials 2024 1.4 (6 links)
960. Reference:WHO WHO - Guidance for best practices for clinical trials 2024 3.2.4 (6 links)
961. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 10.3 (6 links)
962. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 11 (6 links)
963. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 11.2 (6 links)
964. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 13 (6 links)
965. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 2 (6 links)
966. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 3.2 - Consultation (6 links)
967. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 3.2 - Introduction (6 links)
968. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 3.2 - Responsibility (6 links)
969. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 3.3 c) ; e) - g) (6 links)
970. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 3.3 e) - g) (6 links)
971. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.11 (6 links)
972. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.12-001 (6 links)
973. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.12-002 (6 links)
974. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.12-003 (6 links)
975. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.15 (6 links)
976. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.2 (6 links)
977. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.3 (6 links)
978. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.4 - Amendment (6 links)
979. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.4 - Introduction (6 links)
980. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.5 (6 links)
981. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.6 (6 links)
982. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.7 (6 links)
983. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 4.8 - 4.9 (6 links)
984. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 5.12 (6 links)
985. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 5.14 (6 links)
986. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 7.1 - Committee (6 links)
987. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 7.1 - Investigator (6 links)
988. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 7.1 - Sponsor (6 links)
989. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 8 (6 links)
990. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 8.3 (6 links)
991. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 8 - Electronic data handling (6 links)
992. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 9.1 (6 links)
993. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 9.2 (6 links)
994. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - 1.5 Regulatory requirements (6 links)
995. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - adverse event (6 links)
996. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - audit of a trial (6 links)
997. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - contract (6 links)
998. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - contract research organization (CRO) (6 links)
999. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - final report (6 links)
1000. Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - informed consent (6 links)